Clinical Trial Update: A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas [Phase 1, Phase 2]

View source ↗

Summary

A study of DR-01 by Dren Bio is ongoing in Phase 1/Phase 2 to treat several T-cell and NK-cell lymphomas, with recruitment currently underway.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Aggressive Nk-cell Leukemia
• Cutaneous Gamma-delta T-cell Lymphoma
• Enteropathy-associated T-cell Lymphoma
• Extranodal Nk T-cell Lymphoma Nasal Type
• Hepatosplenic T-cell Lymphoma
• Large Granular Lymphocytic Leukemia
• Monomorphic Epitheliotropic Intestinal T-cell Lymphoma
• Subcutaneous Panniculitis-like T-cell Lymphoma

Drugs mentioned

• DR-01

Snippet

Sponsor: Dren Bio | Conditions: LGLL - Large Granular Lymphocytic Leukemia, Primary Cutaneous Gamma-Delta T-Cell Lymphoma | Phase 1, Phase 2 | Status: RECRUITING